Fig. 1: Immune response against SARS-CoV-2 and Variants of Concern after recombinant protein subunit vaccine booster following two-dose inactivated vaccines. | Cell Research

Fig. 1: Immune response against SARS-CoV-2 and Variants of Concern after recombinant protein subunit vaccine booster following two-dose inactivated vaccines.

From: Recombinant protein subunit vaccine booster following two-dose inactivated vaccines dramatically enhanced anti-RBD responses and neutralizing titers against SARS-CoV-2 and Variants of Concern

Fig. 1

a Baseline IFN-γ SFU/million PBMCs against S1, S2 and N peptide at 4–8 months after the second dose. b Baseline antibody response 4–8 months after second dose evaluated by pVNT. c Baseline antibody response 4–8 months after second dose evaluated by sVNT. d Baseline antibody response 4–8 months after second dose evaluated by total anti-RBD antibody. e Baseline antibody response 4–8 months after second dose evaluated by anti-RBD IgG. f IFN-γ SFU/million PBMCs against S1, S2 and N peptide in booster group. The IFN-γ -producing T cell spots were counted on the day of third dose, 14 days after third dose and 28 days after third dose. g Antibody response in boost group evaluated by pVNT. h Antibody response in boost group evaluated by sVNT. i Antibody response in boost group evaluated by total anti-RBD antibody. j Antibody response in boost group evaluated by anti-RBD IgG. k Pseudovirus neutralizing responses by various intervals between previous two vaccinations and the third booster vaccination. l Pseudovirus neutralizing responses after previous two vaccinations and the third booster vaccination against Wuhan-Hu-1 and VOCs, including, B.1.1.7 (Alpha Variant), B.1.351 (Beta Variant), P.1 (Gamma Variant) and B.1.617.2 (Delta Variant) strains. Samples with undetectable levels of IFN-γ SFU/million PBMCs were assigned a value of 20 IFN-γ SFU/million PBMCs. Samples with undetectable levels of sVNT were assigned a value of 20 titer.

Back to article page